<p>Savvy Advisors Inc. 在最近向证券交易委员会提交的文件中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股增加了 14.1%。该基金在季度内购买了 2,508 股后，持有该公司 20,236 股股票。根据其最近向证券交易委员会提交的文件，Savvy Advisors Inc. 在艾伯维的持股价值为 4,240,000 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了在该公司的股份。Brighton Jones LLC 在第四季度将其在艾伯维的股份增加了 17.4%。Brighton Jones LLC 目前拥有 22,912 股该公司的股票，价值 4,072,000 美元，在此期间又购买了 3,401 股。Revolve Wealth Partners LLC 在第四季度将其在艾伯维的持股增加了 72.7%。Revolve Wealth Partners LLC 目前拥有 7,279 股该公司的股票，价值 1,294,000 美元，在此期间又收购了 3,064 股。DRW Securities LLC 在第四季度购买了价值约 798,000 美元的艾伯维新股份。F M Investments LLC 在第四季度将其在艾伯维的持股增加了 13.9%。F M Investments LLC 目前拥有 59,371 股该公司的股票，价值 10,550,000 美元，在上个季度又购买了 7,226 股。最后，Redwood Park Advisors LLC 在第四季度购买了价值约 40,000 美元的艾伯维新股份。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商已对 ABBV 发布了报告。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖艾伯维。他们对该股票设定了 “增持” 评级和 210.00 美元的目标价。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。Raymond James Financial 在 8 月 1 日的报告中将艾伯维的目标价从 227.00 美元上调至 236.00 美元，并给予该股票 “跑赢大盘” 评级。Evercore ISI 在 4 月 28 日的研究报告中将艾伯维的目标价从 204.00 美元上调至 205.00 美元，并给予该公司 “跑赢大盘” 评级。最后，法国巴黎银行在 5 月 8 日的研究报告中将艾伯维的股票评级上调至 “持有”。七位投资分析师对该股票给予了持有评级，十八位给予了买入评级，三位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 214.43 美元。</p>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p><strong>查看我们关于艾伯维的最新研究报告</strong></p>
<h2>艾伯维内部交易</h2>
<p>在相关消息中，执行副总裁 Nicholas Donoghoe 在 8 月 5 日（星期二）出售了 13,295 股艾伯维股票。该股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。出售后，该执行副总裁持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这笔交易代表了他们持股的 18.58% 的减少。该出售在向证券交易委员会的文件中披露，可以通过此超链接访问。内部人士持有该公司 0.25% 的股票。</p>
<h2>艾伯维股票上涨 1.3%</h2>
<ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
<p>艾伯维股票在周五开盘价为 198.77 美元。该公司的 50 日移动平均价格为 189.13 美元，200 日移动平均价格为 190.69 美元。该公司的债务与股本比率为 44.14，流动比率为 0.74，速动比率为 0.64。艾伯维公司 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该股票的市值为 3511.3 亿美元，市盈率为 94.65，市盈增长比率为 1.26，贝塔值为 0.50。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该公司报告每股收益（EPS）为 2.97 美元，低于共识预期的 3.24 美元（差额为 0.27 美元）。该公司在本季度的收入为 154.2 亿美元，而共识预期为 149.3 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。艾伯维的收入同比增长 6.6%。在去年同期，该公司每股收益为 2.65 美元。分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
<h2>艾伯维分红公告</h2>
<p>该公司最近还宣布了一项季度分红，将于 8 月 15 日（星期五）支付。7 月 15 日（星期二）的登记投资者将获得每股 1.64 美元的分红。这相当于年化分红为 6.56 美元，收益率为 3.3%。该分红的除息日期为 7 月 15 日（星期二）。艾伯维的分红支付比率目前为 312.38%。</p>
<h2>艾伯维简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过艾伯维</li>
<li>内部交易可能并不会告诉你你想的那样</li>
<li>3 只推动下一场科技革命的人工智能基础设施股票</li>
<li>3 只沃伦·巴菲特现在值得购买的股票</li>
<li>为什么单片电源的收益和指引引发了市场反弹</li>
<li>通过这些股息之王渡过衰退</li>
<li>AppLovin 第二季度业绩不佳让市场紧张，但华尔街加倍押注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
<p>在你考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Savvy Advisors Inc. 在第一季度将其在艾伯维（AbbVie Inc.，NYSE:ABBV）的持股增加了 14.1%，目前持有 20,236 股，价值 424 万美元。其他机构投资者也调整了他们的持股。分析师为艾伯维设定的共识目标价为 214.43 美元，评级为 “适度买入”。该股票开盘价为 198.77 美元，市值为 3511.3 亿美元。艾伯维报告第二季度每股收益为 2.97 美元，未达到预期，但收入同比增长 6.6%</p>

<p>Savvy Advisors Inc. boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 14.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,236 shares of the company's stock after purchasing an additional 2,508 shares during the quarter. Savvy Advisors Inc.'s holdings in AbbVie were worth $4,240,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Savvy Advisors Inc. 在最近向证券交易委员会提交的文件中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股增加了 14.1%。该基金在季度内购买了 2,508 股后，持有该公司 20,236 股股票。根据其最近向证券交易委员会提交的文件，Savvy Advisors Inc. 在艾伯维的持股价值为 4,240,000 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. DRW Securities LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $798,000. F M Investments LLC grew its holdings in AbbVie by 13.9% during the 4th quarter. F M Investments LLC now owns 59,371 shares of the company's stock valued at $10,550,000 after purchasing an additional 7,226 shares in the last quarter. Finally, Redwood Park Advisors LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $40,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了在该公司的股份。Brighton Jones LLC 在第四季度将其在艾伯维的股份增加了 17.4%。Brighton Jones LLC 目前拥有 22,912 股该公司的股票，价值 4,072,000 美元，在此期间又购买了 3,401 股。Revolve Wealth Partners LLC 在第四季度将其在艾伯维的持股增加了 72.7%。Revolve Wealth Partners LLC 目前拥有 7,279 股该公司的股票，价值 1,294,000 美元，在此期间又收购了 3,064 股。DRW Securities LLC 在第四季度购买了价值约 798,000 美元的艾伯维新股份。F M Investments LLC 在第四季度将其在艾伯维的持股增加了 13.9%。F M Investments LLC 目前拥有 59,371 股该公司的股票，价值 10,550,000 美元，在上个季度又购买了 7,226 股。最后，Redwood Park Advisors LLC 在第四季度购买了价值约 40,000 美元的艾伯维新股份。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have issued reports on ABBV. Cantor Fitzgerald began coverage on AbbVie in a research note on Tuesday, April 22nd. They set an &#34;overweight&#34; rating and a $210.00 price objective on the stock. Citigroup upped their price target on AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, June 11th. Raymond James Financial lifted their price objective on shares of AbbVie from $227.00 to $236.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, August 1st. Evercore ISI boosted their target price on shares of AbbVie from $204.00 to $205.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, April 28th. Finally, BNP Paribas upgraded shares of AbbVie to a &#34;hold&#34; rating in a research report on Thursday, May 8th. Seven investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $214.43.</p>
<div class="lb-trans"><p>几家券商已对 ABBV 发布了报告。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖艾伯维。他们对该股票设定了 “增持” 评级和 210.00 美元的目标价。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。Raymond James Financial 在 8 月 1 日的报告中将艾伯维的目标价从 227.00 美元上调至 236.00 美元，并给予该股票 “跑赢大盘” 评级。Evercore ISI 在 4 月 28 日的研究报告中将艾伯维的目标价从 204.00 美元上调至 205.00 美元，并给予该公司 “跑赢大盘” 评级。最后，法国巴黎银行在 5 月 8 日的研究报告中将艾伯维的股票评级上调至 “持有”。七位投资分析师对该股票给予了持有评级，十八位给予了买入评级，三位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 214.43 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p><strong>View Our Latest Research Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们关于艾伯维的最新研究报告</strong></p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维内部交易</h2>
</div><p>In related news, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Nicholas Donoghoe 在 8 月 5 日（星期二）出售了 13,295 股艾伯维股票。该股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。出售后，该执行副总裁持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这笔交易代表了他们持股的 18.58% 的减少。该出售在向证券交易委员会的文件中披露，可以通过此超链接访问。内部人士持有该公司 0.25% 的股票。</p>
</div><h2>AbbVie Trading Up 1.3%</h2>
<div class="lb-trans"><h2>艾伯维股票上涨 1.3%</h2>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
</div><p>ABBV stock opened at $198.77 on Friday. The business has a fifty day moving average price of $189.13 and a 200 day moving average price of $190.69. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.64. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The stock has a market capitalization of $351.13 billion, a price-to-earnings ratio of 94.65, a P/E/G ratio of 1.26 and a beta of 0.50.</p>
<div class="lb-trans"><p>艾伯维股票在周五开盘价为 198.77 美元。该公司的 50 日移动平均价格为 189.13 美元，200 日移动平均价格为 190.69 美元。该公司的债务与股本比率为 44.14，流动比率为 0.74，速动比率为 0.64。艾伯维公司 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该股票的市值为 3511.3 亿美元，市盈率为 94.65，市盈增长比率为 1.26，贝塔值为 0.50。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.65 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该公司报告每股收益（EPS）为 2.97 美元，低于共识预期的 3.24 美元（差额为 0.27 美元）。该公司在本季度的收入为 154.2 亿美元，而共识预期为 149.3 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。艾伯维的收入同比增长 6.6%。在去年同期，该公司每股收益为 2.65 美元。分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>艾伯维分红公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 8 月 15 日（星期五）支付。7 月 15 日（星期二）的登记投资者将获得每股 1.64 美元的分红。这相当于年化分红为 6.56 美元，收益率为 3.3%。该分红的除息日期为 7 月 15 日（星期二）。艾伯维的分红支付比率目前为 312.38%。</p>
</div><h2>AbbVie Profile</h2>
<div class="lb-trans"><h2>艾伯维简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>3 AI Infrastructure Stocks Powering the Next Tech Revolution</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Why Monolithic Power's Earnings and Guidance Ignited a Rally</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过艾伯维</li>
<li>内部交易可能并不会告诉你你想的那样</li>
<li>3 只推动下一场科技革命的人工智能基础设施股票</li>
<li>3 只沃伦·巴菲特现在值得购买的股票</li>
<li>为什么单片电源的收益和指引引发了市场反弹</li>
<li>通过这些股息之王渡过衰退</li>
<li>AppLovin 第二季度业绩不佳让市场紧张，但华尔街加倍押注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Savvy Advisors Inc.提升了其在艾伯维公司（NYSE:ABBV）的股票持仓